A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | November 2012 |
| End Date: | September 2013 |
| Contact: | For participation information at a USA site use a phone number below. For Site information outside USA please email: |
| Email: | Clinical.Trials@bms.com |
The purpose of this study is to determine the rate of kidney or heart impairment, if any, in
subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials
subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials
Inclusion Criteria:
- Healthy and hepatitis C virus (HCV)-infected subjects who participated in prior Phase
1 trial with BMS-986094/INX-08189 and:
1. Received at least 1 dose of INX-08189 or
2. Received placebo in studies for HCV-infected subjects (INH-189-002 or
INH-189-006)
- Age 18 or older
Exclusion Criteria:
-
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials